GSK’s Combination Meningitis Vaccine Receives FDA Approval
GlaxoSmithKline has announced that its combination meningitis vaccine, MenHibrix has been approved by the US Food and Drug Administration as a protective vaccination for infants against two bacterial diseases.
MenHibrix is a combination of GSK's meningococcal and Hib vaccines and is administered in a four-dose series at 2, 4, 6 and 12 through 15 months of age. The company said that the vaccine will prevent diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.
Commenting on the approval, GSK Vaccines vice president Leonard Friedland said, "MenHibrix gives healthcare providers the option of combining Hib immunization with meningococcal C and Y immunization without increasing the number of shots for infants and toddlers."